A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Goserelin
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 12 Apr 2017 Planned End Date changed from 31 Mar 2022 to 30 Apr 2025.